Primary Pleural Neoplasia: Entities Other Than Diffuse Malignant Mesothelioma

2008 ◽  
Vol 132 (7) ◽  
pp. 1149-1170 ◽  
Author(s):  
Donald G. Guinee ◽  
Timothy Craig Allen
Keyword(s):  
Differential Diagnosis ◽  
Literature Review ◽  
Malignant Mesothelioma ◽  
Correct Diagnosis ◽  
Metastatic Carcinoma ◽  
Data Sources ◽  
Pleural Tumor ◽  
Neoplasm Primary ◽  
Diffuse Malignant Mesothelioma ◽  
Pleural Neoplasms

Abstract Context.—Overwhelmingly, the most common neoplasm involving the pleura is metastatic carcinoma. In contrast, diffuse malignant mesothelioma occurs relatively rarely; however, it is nonetheless the most common neoplasm primary to the pleura. Metastatic carcinoma and diffuse malignant mesothelioma each have their own prognostic and therapeutic characteristics. Other primary pleural neoplasms occur uncommonly or rarely, with their own prognostic and therapeutic characteristics. Objective.—To review primary pleural neoplasms other than diffuse malignant mesothelioma, to better ensure correct diagnosis and optimal assessment of prognosis and treatment. Data Sources.—Literature review and primary material from the authors' institutions. Conclusions.—A nonexhaustive group of uncommon to rare benign and malignant primary pleural neoplasms— other than diffuse malignant mesothelioma—are presented, of which one must be aware in order to maintain an appropriate index of suspicion to include them in the differential diagnosis of a pleural tumor.

Pulmonary Langerhans Cell Histiocytosis and Other Pulmonary Histiocytic Diseases: A Review

2008 ◽  
Vol 132 (7) ◽  
pp. 1171-1181 ◽  
Author(s):  
Timothy Craig Allen
Keyword(s):  
Literature Review ◽  
Langerhans Cell Histiocytosis ◽  
Correct Diagnosis ◽  
Pulmonary Involvement ◽  
Langerhans Cell ◽  
Data Sources ◽  
Primary Material ◽  
Pulmonary Langerhans Cell Histiocytosis

Abstract Context.—Pulmonary Langerhans cell histiocytosis is the most common and best known pulmonary histocytic lesion; however, the realm of pulmonary histiocytic lesions also includes an assortment of uncommon diseases that may exhibit pulmonary involvement. Objective.—To review pulmonary Langerhans cell histiocytosis and other pulmonary histiocytoses to better ensure correct diagnosis and optimal assessment of prognosis and treatment. Data Sources.—Literature review and primary material from the author's institution. Conclusions.—This review discusses the most common pulmonary histocytosis, pulmonary Langerhans cell histiocytosis, and also reviews the uncommon pulmonary histiocytic lesions, which are distinct from pulmonary Langerhans cell histiocytosis.

scholarly journals Ossifying Fibromyxoid Tumor: A Review With Emphasis on Recent Molecular Advances and Differential Diagnosis

2019 ◽  
Vol 143 (12) ◽  
pp. 1504-1512
Author(s):  
Cody S. Carter ◽  
Rajiv M. Patel
Keyword(s):  
Differential Diagnosis ◽  
Correct Diagnosis ◽  
Molecular Genetic ◽  
S100 Protein ◽  
Data Sources ◽  
Low Grade ◽  
Diagnostic Features ◽  
Mesenchymal Neoplasm ◽  
High Index Of Suspicion ◽  
Ossifying Fibromyxoid Tumor

Context.— Ossifying fibromyxoid tumor (OFMT) is a rare, slow-growing mesenchymal neoplasm of uncertain histogenesis with intermediate malignant potential. Objective.— To highlight the most important diagnostic features, including morphologic, immunohistochemical, and molecular findings; to provide comparisons to other entities in the differential diagnosis; and to provide a summary of the clinical features and outcomes in cases reported to date. Data Sources.— The data sources include recently published literature encompassing OFMT and tumors in the histologic differential diagnosis, and cases from institutional files. Conclusions.— Ossifying fibromyxoid tumor is important to recognize because of its low-grade morphology but potential for recurrence and metastasis. Recent molecular analysis has expanded the morphologic spectrum of OFMT, with additional cases discovered that are enriched for aggressive behavior. The diagnosis can often be rendered through a combination of morphology and coexpression of S100 protein and desmin, although only a minority of cases described contain all of these primary features. In cases that do not have all of these features, a high index of suspicion guided by morphology and exclusion of other tumors in the histologic differential diagnosis can lead to the correct diagnosis. Growing access to molecular genetic testing will become increasingly important for correct diagnosis of tumors at the ends of the morphologic spectrum.

scholarly journals Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors

2015 ◽  
Vol 139 (1) ◽  
pp. 55-66 ◽  
Author(s):  
Shaobo Zhu ◽  
Conrad Schuerch ◽  
Jennifer Hunt
Keyword(s):  
Differential Diagnosis ◽  
Salivary Gland ◽  
Literature Review ◽  
Head And Neck ◽  
Head And Neck Tumors ◽  
Data Sources ◽  
Diverse Group ◽  
Immunohistochemical Markers ◽  
Neck Tumors ◽  
Practice Experience

Context Immunohistochemistry is a useful tool for diagnosing salivary gland and head and neck tumors. Objective To review immunohistochemical markers, which can aid in the diagnosis of selected salivary gland and head and neck tumors. Data Sources Literature review and authors' personal practice experience. Conclusions Salivary gland and head and neck tumors include a large diverse group of tumors with complex and overlapping histologic features. Immunohistochemistry plays an important role in resolving the differential diagnosis of some salivary gland and head and neck tumors and can provide information for the prognosis of certain tumors.

Differential Diagnosis of Benign and Malignant Mesothelial Proliferations on Pleural Biopsies

2005 ◽  
Vol 129 (11) ◽  
pp. 1421-1427 ◽  
Author(s):  
Philip T. Cagle ◽  
Andrew Churg
Keyword(s):  
United States ◽  
Differential Diagnosis ◽  
Malignant Mesothelioma ◽  
The United States ◽  
Diagnostic Challenge ◽  
Pleural Biopsy ◽  
Reliable Criterion ◽  
Tissue Invasion ◽  
Reactive Hyperplasia ◽  
Diffuse Malignant Mesothelioma

Abstract Context.—Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia. Design.—Based on previous medical publications, extensive personal consultations, and experience on the United States–Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies. Results.—Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult. Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland. Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion. Conclusions.—Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa. Invasion is the most reliable criterion for determining that a mesothelial proliferation is malignant. When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.

Mycotic Pseudotumor of the Breast Secondary to Cryptococcal Infection: Report of Three Rare Cases and Literature Review

2021 ◽  
pp. 106689692110604
Author(s):  
Velaphi Glenda Makhubela ◽  
Moshawa Calvin Khaba
Keyword(s):  
Differential Diagnosis ◽  
Clinical Practice ◽  
Literature Review ◽  
Surgical Intervention ◽  
Fungal Infections ◽  
Correct Diagnosis ◽  
Breast Mass ◽  
Breast Masses ◽  
Cryptococcal Infection ◽  
Breast Malignancies

Breast masses in clinical practice are often investigated primarily for neoplastic conditions. Breast fungal infections are unusual, and few cases have been reported in the literature. The differential diagnosis for a breast mass should not be limited to neoplastic conditions as there are treatment implications. The correct diagnosis is associated with reduced and unwanted cases of surgical intervention. We describe 3 cases of cryptococcal infection of the breast that clinically masqueraded as breast malignancies.

Pseudoneoplasms of the Nervous System

2010 ◽  
Vol 134 (3) ◽  
pp. 404-416
Author(s):  
Kliment Donev ◽  
Bernd W. Scheithauer
Keyword(s):  
Nervous System ◽  
Differential Diagnosis ◽  
Clinical Picture ◽  
Correct Diagnosis ◽  
Molecular Genetic ◽  
Data Sources ◽  
Pertinent Literature ◽  
Presenting Symptoms ◽  
Radiation Induced ◽  
Physical Findings

Abstract Context.—Pseudoneoplasms of the nervous system vary greatly in nature. Ranging from inflammatory to autoimmune, infectious, malformative, reactive, degenerative, and radiation induced, they all mimic true tumors. Thus, they have the potential to mislead clinicians, radiologists, and pathologists alike. Their clinical and/or neuroimaging and histologic features are readily misinterpreted as tumor. Knowledge of the pitfalls is essential to avoid mismanagement, specifically overtreatment. In such instances, pathologists must take the entire clinical picture into consideration, acquainting themselves with presenting symptoms, physical findings, and neuroimaging. Objective.—To present 10 examples of pseudoneoplasms of the nervous system, analyze the basis for their mimicry, and discuss their differential diagnosis. Data Sources.—Review of the pertinent literature related to pseudoneoplasms of the nervous system and review of the consultation files of one of the authors (B.W.S.). Conclusions.—The identification of tumor mimics may be difficult under the best of circumstances, and maintaining a broad differential diagnosis as well as application of a variety of immunocytochemical and occasionally ultrastructural and/or molecular genetic methods is essential to arrive at a correct diagnosis.

Epithelioid and Epithelial Neoplasms of Bone

2007 ◽  
Vol 131 (2) ◽  
pp. 205-216 ◽  
Author(s):  
Andrea T. Deyrup ◽  
Anthony G. Montag
Keyword(s):  
Differential Diagnosis ◽  
Metastatic Carcinoma ◽  
Data Sources ◽  
Vascular Lesions ◽  
Controversial Issues ◽  
Clinical Context ◽  
Pertinent Literature ◽  
Metastatic Lesions ◽  
Epithelial Neoplasms ◽  
Epithelial Lesions

AbstractContext.—Epithelioid and epithelial neoplasms seen in bone are rare and include epithelioid variants of vascular lesions, osteoblastoma, osteosarcoma, chordoma, and chondroblastoma as well as adamantinoma and metastatic carcinoma.Objective.—To provide an overview of tumors with epithelioid histology and address the clinical context and diagnostic issues.Data Sources.—Pertinent literature is reviewed with emphasis on recent and controversial issues.Conclusions.—The differential diagnosis in epithelioid/ epithelial lesions of bone is limited. The primary consideration in many cases is distinguishing primary from metastatic lesions.

Application of Immunohistochemistry to the Diagnosis of Malignant Mesothelioma

2008 ◽  
Vol 132 (3) ◽  
pp. 397-401 ◽  
Author(s):  
Alberto M. Marchevsky
Keyword(s):  
Differential Diagnosis ◽  
Malignant Mesothelioma ◽  
Data Sources ◽  
Evidence Based ◽  
Epithelial Markers ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Cytokeratin 5 ◽  
Transcription Factor 1 ◽  
Other Neoplasms

Abstract Context.—The diagnosis of malignant mesothelioma (MM) is rendered with the aid of immunohistochemistry to demonstrate the presence of “mesothelial,” “epithelial,” or “sarcomatous” differentiation. Antibody panels that have been proposed for the distinction between MM and other neoplasms usually include 2 or more epithelial markers used to exclude the diagnosis of a carcinoma, such as monoclonal and polyclonal carcinoembryonic antigen, Ber-EP4, B72.3, CD15, MOC-31, thyroid transcription factor 1, BG8, and others, and 2 or more mesothelial markers used to confirm the diagnosis of MM, such as cytokeratin 5/6, calretinin, HBME-1, thrombomodulin, WT-1, mesothelin, D2-40, and podoplanin. In general, most antibody panels provide excellent sensitivity and specificity for the differential diagnosis between MM epithelial variant and adenocarcinoma, particularly of lung origin. However, the accuracy of these markers is lower for the diagnosis of sarcomatous MM and for the differential diagnosis between MM and squamous cell carcinoma and carcinomas of renal, ovarian, and other origin. Objective.—To identify optimal antibody panels for the diagnosis of MM. Data Sources.—Literature review to determine how many and which mesothelial and epithelial markers need to be included in differential diagnosis antibody panels. Conclusions.—Various antibody panels have been recommended for the diagnosis of MM, with no overall consensus about how many and which markers should be used. A recent study with Bayesian statistics has demonstrated that the use of many markers does not provide higher diagnostic accuracy than the use of selected single antibodies or various combinations of only 2 markers. There is a need for the development of evidence-based or consensus-based guidelines for the diagnosis of MM in different differential diagnosis situations.

Sign in / Sign up

Export Citation Format

Share Document